<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00127036</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-13449</org_study_id>
    <secondary_id>R21 CA10135</secondary_id>
    <secondary_id>XEL390</secondary_id>
    <secondary_id>2005-0729</secondary_id>
    <nct_id>NCT00127036</nct_id>
  </id_info>
  <brief_title>Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)</brief_title>
  <official_title>A Multicenter Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the investigators can predict the sensitivity or
      resistance of colon cancer to the two available first line chemotherapy agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal cancer is the third largest cause of cancer mortality in the United States. The
      treatment of metastatic colorectal cancer is undergoing rapid improvement. Currently, there
      are two major chemotherapy regimens, which can both be combined with anti-angiogenesis
      treatment. These regimens are 5-Fluorouracil (5-FU) + irinotecan and 5-FU + oxaliplatin. Each
      therapy has roughly similar rates of response, but it is unclear which specific therapy would
      benefit which patients. The advent of genome wide expression analysis provides a tool to
      analyze these differences. In the microarray analysis of colon cancer outcome trial,
      sponsored by the National Institutes of Health (NIH) and Moffitt Cancer Center, patients with
      newly diagnosed metastatic colon cancer are biopsied and samples are preserved in ribonucleic
      acid (RNA) later. Patients are then randomized to either one of two state of the art
      regimens: capecitabine + irinotecan + avastin (bevacizumab) or capecitabine + oxaliplatin +
      avastin. Response to chemotherapy, time to progression, and overall survival are end points
      of this trial. Once accrual of patients has been met, the investigators will compare genome
      wide expression patterns for each group.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    drug now on market
  </why_stopped>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Per Treatment Arm, Per Tumor Tissue Response Classifier</measure>
    <time_frame>30 Days After End of Treatment - Average of 6 Months</time_frame>
    <description>Investigators would develop tumor tissue classifiers to predict response to the XELOX arm or XELIRI arm; with gene expression profiles on 75 patients on each of 2 arms, construct 2 classifiers to distinguish responders (complete responses, partial responses, stable disease) from non-responders (progressive disease).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Per Treatment Arm, With Overall Survival (OS)</measure>
    <time_frame>30 Days After End of Treatment - Average of 6 Months</time_frame>
    <description>Investigators planned to evaluate the overall survival of colorectal cancer (CRC) patients treated with XELOX + bevacizumab (Arm A) or XELIRI + bevacizumab (Arm B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>30 Days After End of Treatment - Average of 6 Months</time_frame>
    <description>Review of Serious Adverse Events (SAEs) To assess the toxicity associated with Arms A and B. Response rates and toxicity rates for each arm were to be estimated and exact (using Casella's method) 95% confidence intervals for those proportions computed. With the anticipated 75 patients in each arm, these estimated proportions would have standard errors not exceeding 7%.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Adenocarcinoma</condition>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>XELOX + Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A: Anticipated 75 Patients - Drug: XELOX (which is Capecitabine + Oxaliplatin) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XELIRI + Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B: Anticipated 75 Patients - Drug: XELIRI (which is Capecitabine + Irinotecan) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XELOX</intervention_name>
    <description>XELOX: Oxaliplatin 130 mg/m^2 intravenously (IV); Capecitabine 825 mg/m^2 by mouth (po)</description>
    <arm_group_label>XELOX + Bevacizumab</arm_group_label>
    <other_name>Oxaliplatin and Capecitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XELIRI</intervention_name>
    <description>XELIRI: Irinotecan 240 mg/m^2 IV; Capecitabine 825 mg/m^2 by mouth (po)</description>
    <arm_group_label>XELIRI + Bevacizumab</arm_group_label>
    <other_name>Irinotecan and Capecitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>7.5 mg/kg intravenously (IV)</description>
    <arm_group_label>XELOX + Bevacizumab</arm_group_label>
    <arm_group_label>XELIRI + Bevacizumab</arm_group_label>
    <other_name>Avastin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent prior to study-specific screening procedures, with
             the understanding that the patient has the right to withdraw from the study at any
             time, without prejudice

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Patients with metastatic, Response Evaluation Criteria In Solid Tumors (RECIST)
             measurable, adenocarcinoma of the colon and/or rectum are eligible provided their
             disease is metastatic to the liver. The liver metastatic disease should be confirmed
             cytologically or histologically at the time of study biopsy or prior to the study
             biopsy. All pre-study scans documenting disease must be done &lt; 4 weeks prior to
             registration.

          -  Patients must have had no prior treatment with either irinotecan or oxaliplatin.

          -  Prior adjuvant therapy with fluoropyrimidine is allowed.

          -  Prior radiotherapy is allowed, but patients should have measurable disease outside the
             radiation port and/or progressive disease within the previously radiated volume. In
             addition, it must be at least 2 weeks since administration of radiation therapy and
             all signs of toxicity must have abated.

          -  Patients must have adequate renal and hepatic function (creatinine &lt; 1.6 and
             calculated creatinine clearance [Cockcroft-Gault equation] &gt; 60 ml/min; bilirubin &lt;
             2.0; and serum glutamic oxaloacetic transaminase [SGOT] less than 3 x normal limits)
             obtained within 4 weeks prior to registration.

          -  Alkaline phosphatase &lt; 2.5 x upper normal limit (or &lt; 5 x upper normal limit in the
             case of liver metastases or &lt; 10 x upper normal limit in the case of bone disease)

          -  Patients must have absolute neutrophil count (ANC) &gt; 1500/mm³ and platelet count &gt;
             100,000/mm³ within 4 weeks prior to registration.

          -  Have a negative serum or urine pregnancy test within 7 days prior to starting therapy
             (female patients of childbearing potential)

        Exclusion Criteria:

          -  Pregnant and breast-feeding women are excluded from the study because effects on the
             fetus are unknown and there may be a risk of increased fetal wastage.

          -  Women of childbearing potential with either a positive or no pregnancy test (serum or
             urine) at baseline. Women/men of childbearing potential not using a reliable and
             appropriate contraceptive method. (Postmenopausal women must have been amenorrheic for
             at least 12 months to be considered of non-childbearing potential.) Patients will
             agree to continue contraception for 30 days from the date of the last study drug
             administration.

          -  Serious, uncontrolled, concurrent infection(s). Patients must have no evidence of
             significant active infection (e.g., pneumonia, peritonitis, wound abscess, etc.) at
             time of study entry.

          -  Life expectancy &lt; 3 months

          -  Any prior fluoropyrimidine therapy (unless given in an adjuvant setting and completed
             at least 6 months earlier)

          -  Prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity
             to 5-fluorouracil or known dihydropyrimidine dehydrogenase (DPD) deficiency

          -  Treatment for other carcinomas within the last 5 years, except cured non-melanoma skin
             and treated in-situ cervical cancer

          -  Participation in any investigational drug study

          -  Clinically significant cardiac disease of New York Heart Association Class III or
             greater (e.g. congestive heart failure, symptomatic coronary artery disease and
             cardiac arrhythmias not well controlled with medication) or myocardial infarction
             within the last 12 months.

          -  Evidence of central nervous system (CNS) metastases (unless CNS metastases have been
             stable for &gt; 3 months) or history of uncontrolled seizures, central nervous system
             disorders or psychiatric disability judged by the investigator to be clinically
             significant, precluding informed consent, or interfering with compliance of oral drug
             intake.

          -  Other serious uncontrolled medical conditions that the investigator feels might
             compromise study participation

          -  Major surgery, open biopsy, or significant trauma injury within 28 days prior to Day 0

          -  Lack of physical integrity of the upper gastrointestinal tract or malabsorption
             syndrome

          -  Known, existing uncontrolled coagulopathy

          -  Impaired renal function (estimated creatinine clearance &lt; 60ml/min as calculated with
             Cockcroft-Gault equation

          -  Unwillingness to give written informed consent

          -  Unwillingness to participate or inability to comply with the protocol for the duration
             of the study

          -  Urine protein: creatinine ratio &gt; 1.0 at screening

          -  Blood pressure of &gt; 150/100 mmHg

          -  Unstable angina

          -  Clinically significant peripheral vascular disease

          -  Arterial thrombotic events, stroke or transient ischemic attack (TIA) within the last
             6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Strosberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center &amp; Research Institute / University of South Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Broward Medical Center</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward General Medical Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Ft. Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Care &amp; Research - Watson Clinic</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fawcett Memorial Hospital</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33592</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin Memorial</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34994</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallahassee Memorial Hospital</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Oncology</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Space Coast Medical Associates</name>
      <address>
        <city>Titusville</city>
        <state>Florida</state>
        <zip>32796</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Candler Health System</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Nebraska Cancer Center</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org</url>
    <description>H. Lee Moffitt Cancer Center &amp; Research Institute Web Page</description>
  </link>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Clinical Trials website</description>
  </link>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2005</study_first_submitted>
  <study_first_submitted_qc>August 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2005</study_first_posted>
  <results_first_submitted>January 5, 2012</results_first_submitted>
  <results_first_submitted_qc>March 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 5, 2012</results_first_posted>
  <last_update_submitted>February 20, 2017</last_update_submitted>
  <last_update_submitted_qc>February 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colon</keyword>
  <keyword>adenocarcinoma</keyword>
  <keyword>adenocarcinoma-colon</keyword>
  <keyword>adenocarcinoma-rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>XELOX + Bevacizumab</title>
          <description>Arm A: Anticipated 75 Patients - Drug: XELOX (which is Capecitabine + Oxaliplatin) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression</description>
        </group>
        <group group_id="P2">
          <title>XELIRI + Bevacizumab</title>
          <description>Arm B: Anticipated 75 Patients - Drug: XELIRI (which is Capecitabine + Irinotecan) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26">26 Participants were evaluable.</participants>
                <participants group_id="P2" count="20">20 Participants were evaluable.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Insufficient Data for Analysis</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>XELOX + Bevacizumab</title>
          <description>Arm A: Anticipated 75 Patients - Drug: XELOX (which is Capecitabine + Oxaliplatin) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression</description>
        </group>
        <group group_id="B2">
          <title>XELIRI + Bevacizumab</title>
          <description>Arm B: Anticipated 75 Patients - Drug: XELIRI (which is Capecitabine + Irinotecan) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.5" lower_limit="39" upper_limit="88"/>
                    <measurement group_id="B2" value="64" lower_limit="38" upper_limit="82.5"/>
                    <measurement group_id="B3" value="63" lower_limit="38" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Per Treatment Arm, Per Tumor Tissue Response Classifier</title>
        <description>Investigators would develop tumor tissue classifiers to predict response to the XELOX arm or XELIRI arm; with gene expression profiles on 75 patients on each of 2 arms, construct 2 classifiers to distinguish responders (complete responses, partial responses, stable disease) from non-responders (progressive disease).</description>
        <time_frame>30 Days After End of Treatment - Average of 6 Months</time_frame>
        <population>Low accrual and early termination prevented us from performing the planned analysis. Too few patients had both clinical and microarray data.</population>
        <group_list>
          <group group_id="O1">
            <title>XELOX + Bevacizumab</title>
            <description>Arm A: Anticipated 75 Patients - Drug: XELOX (which is Capecitabine + Oxaliplatin) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression</description>
          </group>
          <group group_id="O2">
            <title>XELIRI + Bevacizumab</title>
            <description>Arm B: Anticipated 75 Patients - Drug: XELIRI (which is Capecitabine + Irinotecan) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Per Treatment Arm, Per Tumor Tissue Response Classifier</title>
          <description>Investigators would develop tumor tissue classifiers to predict response to the XELOX arm or XELIRI arm; with gene expression profiles on 75 patients on each of 2 arms, construct 2 classifiers to distinguish responders (complete responses, partial responses, stable disease) from non-responders (progressive disease).</description>
          <population>Low accrual and early termination prevented us from performing the planned analysis. Too few patients had both clinical and microarray data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Per Treatment Arm, With Overall Survival (OS)</title>
        <description>Investigators planned to evaluate the overall survival of colorectal cancer (CRC) patients treated with XELOX + bevacizumab (Arm A) or XELIRI + bevacizumab (Arm B).</description>
        <time_frame>30 Days After End of Treatment - Average of 6 Months</time_frame>
        <population>Low accrual and early termination prevented us from performing the planned analysis. Too few patients had both clinical and microarray data.</population>
        <group_list>
          <group group_id="O1">
            <title>XELOX + Bevacizumab</title>
            <description>Arm A: Anticipated 75 Patients - Drug: XELOX (which is Capecitabine + Oxaliplatin) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression</description>
          </group>
          <group group_id="O2">
            <title>XELIRI + Bevacizumab</title>
            <description>Arm B: Anticipated 75 Patients - Drug: XELIRI (which is Capecitabine + Irinotecan) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Per Treatment Arm, With Overall Survival (OS)</title>
          <description>Investigators planned to evaluate the overall survival of colorectal cancer (CRC) patients treated with XELOX + bevacizumab (Arm A) or XELIRI + bevacizumab (Arm B).</description>
          <population>Low accrual and early termination prevented us from performing the planned analysis. Too few patients had both clinical and microarray data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs)</title>
        <description>Review of Serious Adverse Events (SAEs) To assess the toxicity associated with Arms A and B. Response rates and toxicity rates for each arm were to be estimated and exact (using Casella’s method) 95% confidence intervals for those proportions computed. With the anticipated 75 patients in each arm, these estimated proportions would have standard errors not exceeding 7%.</description>
        <time_frame>30 Days After End of Treatment - Average of 6 Months</time_frame>
        <population>All participants.</population>
        <group_list>
          <group group_id="O1">
            <title>XELOX + Bevacizumab</title>
            <description>Arm A: Anticipated 75 Patients - Drug: XELOX (which is Capecitabine + Oxaliplatin) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression</description>
          </group>
          <group group_id="O2">
            <title>XELIRI + Bevacizumab</title>
            <description>Arm B: Anticipated 75 Patients - Drug: XELIRI (which is Capecitabine + Irinotecan) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs)</title>
          <description>Review of Serious Adverse Events (SAEs) To assess the toxicity associated with Arms A and B. Response rates and toxicity rates for each arm were to be estimated and exact (using Casella’s method) 95% confidence intervals for those proportions computed. With the anticipated 75 patients in each arm, these estimated proportions would have standard errors not exceeding 7%.</description>
          <population>All participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years, 5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>XELOX + Bevacizumab</title>
          <description>Arm A: Anticipated 75 Patients - Drug: XELOX (which is Capecitabine + Oxaliplatin) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression</description>
        </group>
        <group group_id="E2">
          <title>XELIRI + Bevacizumab</title>
          <description>Arm B: Anticipated 75 Patients - Drug: XELIRI (which is Capecitabine + Irinotecan) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC V3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bilirubin - hospitalized</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distention</sub_title>
                <description>Also experienced pain</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>1 on Arm A also experienced vomiting and dehydration</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Choking incident while taking tablet</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Also experienced vomiting and abdominal pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>2 in Arm A and 1 in Arm B also had vomiting. 2 in Arm B also had nausea.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhea - persistent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Epigastric pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI - Rectum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>2 in Arm A and 3 in Arm B also experienced vomiting. 2 in Arm B also experienced diarrhea.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Obstructing lesion of the colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Perforation, GI - Duodenum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Small bowel obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>2 in Arm A and 3 in Arm B also experienced nausea. 1 in Arm B also experienced diarrhea.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10^9/L)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pain - headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Death due to disease progression - liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was Terminated early, not Completed. Study Drug now on the market. Due to slow accrual, too few patients who had both clinical and microarray data to perform the proposed analysis. 65 of 92 patients consented were assigned to treatment arms.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jonathan Strosberg, M.D.</name_or_title>
      <organization>H. Lee Moffitt Cancer Center and Research Institute</organization>
      <phone>813-745-2069</phone>
      <email>jonathan.strosberg@moffitt.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

